Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
This FAERS analysis confirms ixekizumab's established safety profile while identifying critical demographic-specific and delayed-onset signals. Continuous pharmacovigilance is warranted to optimize risk management, particularly for cardiovascular monitoring in high-risk males and antiviral prophylaxis in elderly patients.
Authors
- Y F Cheng
- Jun Niu (ORCID: https://orcid.org/0000-0001-7371-917X)
- Jingyi Ma (ORCID: https://orcid.org/0000-0003-2978-1413)
Institutions
- General Hospital of Shenyang Military Region (CN)
- China Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1371/journal.pone.0323973
- Citations
- 3
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 3.92
Funders
- Department of Science and Technology of Liaoning Province